Open AccessCumulative gadodiamide administration leads to brain gadolinium deposition in early MS
Author(s) -
Robert Zivadinov,
Niels Bergsland,
Jesper Hagemeier,
Deepa Ramasamy,
Michael G. Dwyer,
Ferdinand Schweser,
Channa Kolb,
Bianca WeinstockGuttman,
David Hojnacki
Publication year - 2019
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000007892
Subject(s) - gadodiamide , medicine , nuclear medicine , pons , dentate nucleus , hyperintensity , magnetic resonance imaging , globus pallidus , multiple sclerosis , gadolinium , radiology , central nervous system , cerebellum , basal ganglia , materials science , psychiatry , metallurgy
Frequent administration of gadolinium-based contrast agents in multiple sclerosis (MS) may increase signal intensity (SI) unenhanced T1-weighted imaging MRI throughout the brain. We evaluated the association between lifetime cumulative doses of gadodiamide administration and increased SI within the dentate nucleus (DN), globus pallidus (GP), and thalamus in patients with early MS.